Navigation
Market Outlook Stock Screener Dividend Calendar Event Calendar Rating of shares Markets News
Try free

Bio-Path Holdings

NASDAQ BPTH
$2.56 -0.16 -5.88%
Today share price
USA
Sector: Healthcare Industry: Biotechnology
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Index: 18 %
Market cap

Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.

1.68M
EV

Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
731.96K
Beta

Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
1.92
Shares

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
618.00K
YTD

Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
487.47 %

Upcoming events Bio-Path Holdings

All events
No upcoming events scheduled

Overview

Financials

Key Metrics

Dividends

Industry overview

Events

Stock chart Bio-Path Holdings

Stock analysis Bio-Path Holdings

Indicator Company Industry
P/E (LTM)

Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.

More
-0.10 27.58
P/BV (LTM)

Shows the ratio of the market price of the share to the current book value.

More
3.81 3.97
EV/EBITDA (LTM)

Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.

More
-0.05 10.54
Net Debt/EBITDA (LTM)

A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.

More
0.06 0.24
ROE (LTM)

Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.

More
-3,641.50 10.75

Price change Bio-Path Holdings per year

3.12$ 9.40$
Min Max

Summary analysis Bio-Path Holdings

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure Bio-Path Holdings

Revenue and net income Bio-Path Holdings

All parameters

Stock news Bio-Path Holdings

All news
7 November 2022 в 21:30

Bio-Path Holdings Shares Drop 44% After Direct Offering Prices

7 November 2022 в 21:30

Bio-Path Holdings Shares Drop 44% After Direct Offering Prices

12 April 2022 в 23:25

Bio-Path Holdings Shares Rise 11% After Data From BP1003 Study

12 April 2022 в 23:25

Bio-Path Holdings Shares Rise 11% After Data From BP1003 Study

About company Bio-Path Holdings

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. The company is also developing Liposomal Bcl-2 for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 that is in preclinical stage for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and prexigebersen-A for various solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.
Address:
4710 Bellaire Boulevard, Bellaire, TX, United States, 77401
Company name: Bio-Path Holdings
Issuer ticker: BPTH
ISIN: US09057N3008
Country: USA
Exchange: NASDAQ
Currency: $
IPO date: 2008-03-04
Sector: Healthcare
Industry: Biotechnology
Site: https://www.biopathholdings.com

On which stock exchange are Bio-Path Holdings (BPTH) stocks traded?

Bio-Path Holdings (BPTH) stocks are traded on NASDAQ.

What is the ticker of Bio-Path Holdings stocks (BPTH)?

The stock ticker of Bio-Path Holdings’s stocks or in other words, the code is BPTH. The stocks are currently listed on the NASDAQ exchange.

In which sector and industry does Bio-Path Holdings (BPTH) operate?

According to the GICS (Global Industry Classification Standard) classification developed jointly by MSCI and Standard & Poor's, Bio-Path Holdings (BPTH) belongs to the «Healthcare» sector and the «Biotechnology» industry.

In what currency are Bio-Path Holdings (BPTH) stocks traded?

Bio-Path Holdings (BPTH) stocks are traded on the NASDAQ exchange in dollars.

What is the price of Bio-Path Holdings (BPTH) stocks today?

The current price of Bio-Path Holdings stocks on 15.05.2024 is 2.56 dollars. per share.

What is the dynamics of Bio-Path Holdings (BPTH) stocks from the beginning of the year?

Bio-Path Holdings (BPTH) quotes have increased by 419.8% from the beginning of the year up to 2.56 dollars. per 1 stocks.

How much did Bio-Path Holdings (BPTH) stocks increase in мае 2024?

This month Bio-Path Holdings (BPTH) quotes have increased by -7.25% to 2.56 dollars. per share.

How much are Bio-Path Holdings (BPTH) stocks worth?

Today, on October, 15.05.2024 Bio-Path Holdings’s (BPTH) stocks cost 2.56 dollars..

What is the market capitalization of Bio-Path Holdings (BPTH)?

Capitalization is the market value of Bio-Path Holdings (BPTH) is calculated as the number of issued stocks multiplied on the current quotation price. Thus, on 15.05.2024, the market capitalization of Bio-Path Holdings (BPTH) is estimated at about 1680960 dollars.